title: [Effect of treatment for hypocellular myelodysplastic syndromes by a low dose qinghuang powder combined with Chinese drugs for Shen supplementing and Pi invigorating: a clinical observation].
abstract: OBJECTIVE
  To observe the clinical efficacy of a low dose Qinghuang Powder (QP) combined with Chinese drugs for Shen supplementing and Pi invigorating (CDSSPI) in treatment of hypocellular myelodysplastic syndromes (hypo-MDS).
  
  
  METHODS
  Totally 33 hypo-MDS patients enrolled in this study came from outpatient clinics between November 2011 and December 2012. A self-control method was used in this study. Patients took QP (0.4 g per day) combined with CDSSPI (one dose per day), and Stanozolol Tablet (2 mg each time, three times per day), 3 months as one therapeutic course, a total of 2 courses. The clinical efficacy was evaluated timely at the end of each therapeutic course. The venous blood was withdrawn before treatment, at month 3 and 6 after treatment. Changes of neutrophils (ANC), hemoglobin (Hb), and platelet (PLT) were mainly observed.
  
  
  RESULTS
  Totally 31 patients in this study finished the treatment. Three months after treatment ANC, Hb, and PLT increased more than before treatment (P < 0.05). Six months after treatment Hb and PLT increased (P < 0.01, P < 0.05), but with no statistical difference in ANC (P > 0.05). Hb increased higher at month 6 after treatment than at month 3 after treatment (P < 0.01), but with no statistical difference in ANC or PLT (P > 0.05). After 3-month treatment the number of hematologic progress, stability, disease progression were: 13 cases (41.9%), 15 cases (48.4%), and 3 cases (9.7%), respectively; after 6-month treatment the number of hematologic improvement, stability, and disease progression were: 18 cases (58.1%), 7 cases (22.6%), 6 cases (19.3%), respectively. There was no significant difference between 3-month efficacy and 6-month efficacy (P > 0.05). There was no correlation between the efficacy and ages of hypo-MDS patients or the efficacy and courses of hypo-MDS patients (P > 0.05).
  
  
  CONCLUSIONS
  A low dose QP combined with CDSSPI showed confirmative efficacy in treatment of hypo-MDS. But the efficacy had little correlation with ages and courses of hypo-MDS patients.
authors: Qing-Bing
authors: QB
authors: Zhou
authors: Hong-Zhi
authors: HZ
authors: Wang
authors: Fei
authors: F
authors: Gao
authors: Xu-Dong
authors: XD
authors: Tang
authors: Shu
authors: S
authors: Xu
authors: Xiao-Hong
authors: XH
authors: Yang
authors: Yong-Gang
authors: YG
authors: Xu
authors: Xiao-Mei
authors: XM
authors: Hu
authors: Rou
authors: R
authors: Ma
mesh_terms: D001152:Arsenicals / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004365:Drugs, Chinese Herbal / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006454:Hemoglobins; D006801:Humans; D008516:Medicine, Chinese Traditional / Q000379:methods; D009190:Myelodysplastic Syndromes / Q000188:drug therapy*; D009504:Neutrophils; D008517:Phytotherapy / Q000379:methods
chemical_list: D001152:Arsenicals; D004365:Drugs, Chinese Herbal; D006454:Hemoglobins; C570774:qinghuang